Construction of an adenovirus-based vaccine for prevention and therapy of cervical intraepithelial neoplasia (CIN) and cervical cancer

Cervical cancer belongs to the most common cancers among women worldwide. About 70% of cervical cancer cases are associated with infection by HPV type 16 and 18. Constitutive expression of viral oncogenes E6 and E7 in malignant cells makes them a favourable target for immunotherapeutic strategies. Currently, prophylactic vaccines have been developed, which target only late capsid proteins L1 and L2. So far, there are no therapeutic vaccines available that induce effective cellular immunity against HPV-positive cancer cells and its precursor lesions. Constructing a recombinant gene derived from E6 and E7 oncogene…